Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes

Journal of Medical Genetics

Volumn 35, Issue 2, 1998, Pages 116-121

  Chang Claude, Jenny ^a   Dong, Juan ^a   Schmidt, Silke ^b   Shayeghi, Maryam ^b   Komitowski, Dymitr ^c   Becher, Heiko ^c   Stratton, Michael R ^a   Royer Pokora, Brigitte ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cancer risks; Hereditary breast cancer; Pedigree

Indexed keywords

BRCA1 PROTEIN; DNA;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GERM LINE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PEDIGREE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0031971484     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.35.2.116     Document Type: Article

References (38)

1. Eby N, Chang-Claude J, Bishop T. Familial risk and genetic susceptibility for breast cancer. Cancer Causes and Control 1994;S:458-70.
2. Mild Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
3. Vooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378: 789-92.
4. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-7.
5. Ford D, Hasten DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
6. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCAl-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
7. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 1996;5: 1515-19.
8. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52:678-701.
9. Narod SA, Ford D, Devilee P, et al and Breast Cancer Linkage Consortium. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56:254-64.
10. Steichen-Gersdorf E, Gallion HH, Ford D, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17ql221. Am J Hum Genet 1994;55:870-5.
11. Couch FJ, Farid LM, de Shano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13:123-5.
12. Couch FJ, Veber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1): gene. Breast Cancer Information Core. Hum Mutât 1996;8:8-18.
13. Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120-2.
14. Castilla LH, Couch FJ, Erdos MR, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994;8:387-91.
15. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8:399-404.
16. Serova O, Montagna Ai, Torchard D, et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 1996;58:42-51.
17. Peelen T, Cornells RS, van Vliet M, et al. The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2. Ear J Hum Genet 1996;4:225-30.
18. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
19. Andersen TI, Borresen AL, Moller P. A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet 1996;59:486-7.
20. Johannsson O, Ostermeyer EA, Hâkansson S, a al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in Southern Sweden. Am J Hum Genet 1996;58: 441-50.
21. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;S6: 3663-5.
22. Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-8.
23. Thorlacius S, Olafsdortir G, Tryggvadottir L, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-19.
24. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995;273:53541.
25. Hamann U, Becher H, Zimmermann T, Pella K, Bastert G, Chang-Claude J. German family study on hereditary breast/ovarian cancer. JMed Genet 1996;33:633-5.
26. Ganguly A, Rock MJ, Prockop DJ. Confirmation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DANN fragments: evidence for solvent-induced bends in DANN heteroduplexes (published erratum appears in Proc Nad Acad Sei USA 1994;91:5217). Proc Nat! Acad Sei USA 1993;90:10325-9.
27. Dong J, Chang-Claude J, Wu Y, et al. A high proportion of recurrent and novel mutations in the BRCA1 gene in German breast/ovarian families with clustering of mutations in the 3' third of the gene. (Submitted.)
28. Lathrop GM, Lalouel JM, Julier C, On J. Strategies for multilocus linkage analysis in humans. Proc Nad Acad Sei USA 1984;81:3443-6.
29. Claus EB, Risch N, Thompson VD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am JHum Genet 1991;48:232-42.
30. Ott J. Analysis of human genetic linkage. Baltimore: The Johns Hopkins University Press, 1991.
31. Schmidt S, Becher H, Chang-Claude J. Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives. Hum Genet (in press.)
32. Margarittc-Jeannin P, Essioux L, Bonaiti-Pellié C, ClergetDarpoux F. Genetic counseling in breast cancer: sensitivity to parameter values and to available information. Ann Genet 1995;38:19-25.
33. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Breast Cancer Linkage Consortium. Risks of cancer in BRCAl-mutation carriers. Lancet 1994;343:692-5.
34. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 1996;S6: 3409-14.
35. Gudmundsson J, Johannesdottir G, Bergthprsson JT, et al. Different tumor types from BRCA2 carriers show wildtype chromosome deletions on 13ql2-ql3. Cancer Res 1995;5S:4830-2.
36. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
37. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Nat! Cancer Insi 1997;89:227-38.
38. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Breast Cancer Linkage Consortium. Risks of cancer in BRCAl-mutation carriers. Lancet 1994;343:692-5.